Wisconsin Alumni Research Foundation

Daniel Elmer Butz

Mark Eric Cook

Warren Paul Porter

Fariba Masoumeh Assadi-Porter

Jordan Marshall Sand

Hamid Reza Eghbalnia

Alexis Jo Piepenburg

Zhouzheng Ren

Leah D Whigham

Marco Tonelli

Dale A Schoeller

David H Abbott

Hamid R Eghbalnia

Described herein are peptides from secretory phospholipase A-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.

Compositions and methods for the treatment of systemic inflammatory response syndromes

Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen.

Method for improving resistance to breakage and eggshell strength

Described herein are methods of determining energy balance in individuals such as exercising individuals, individuals consuming aC-enriched test composition and individuals consuming a fixed diet with a known &#x3b4;C. The &#x3b4;C pre- and post-exercise, or pre- and post-consumption of the test beverage or fixed diet indicate whether the individual is in neutral or positive energy balance, or in energy deficit. The methods are particularly useful for individuals participating in weight management programs, and individuals under the care of health care professionals.

Methods of determining energy balance using breath carbon isotope ratios

FGF-23 epitope peptide for improving resistance to breakage and eggshell strength

Methods are disclosed for distinguishing whether an animal is experiencing a bacterial infection or a viral infection. One monitors breath taken from the animal over time to measure the relative amount of a first breath stable isotope to a second breath stable isotope therein over time. A quick change in the isotope ratios within several hours from the likely infection is indicative of a bacterial infection. A delayed change in the isotope ratios, followed by periodic repeated alterations in the ratios, is indicative of viral infection. The methods are particularly efficient when using cavity ringdown spectroscopy for the monitoring. They may be used for monitoring a patient already admitted to a hospital, or for monitoring a patient initially complaining of adverse symptoms, or for triage, or for collectively monitoring a population of animals.

Identification of disease characteristics using isotope ratios in breath

The methods described herein are based on the observation that oscillations in breath isotope ratio data can be used for the purpose of identifying an 'unhealthy' state in an organism such as a human. Described herein are methods of determining the state of health of an individual, such as the transition from healthy to infected, by identifying changes in oscillation modes in breath isotope ratio data. Changes in the frequency and/or amplitude of the oscillation modes are correlated with the heath of the individual. The methods can advantageously be used to provide information about the health of an individual in shorter periods of time than previous methods.

Detection of rate changes in systematic oscillations of metabolic athways by monitoring isotope ratios

The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.

Growing community of inventors

Madison, WI, United States of America

Daniel Elmer Butz